Answers are grounded in this paper and cite their sources.
Article1 March 1965Combined Vinblastine and Chlorambucil Therapy of Hodgkin's DiseaseMORTIMER J. LACHER, M.D., JOHN R. DURANT, M.D.MORTIMER J. LACHER, M.D.Search for more papers by this author, JOHN R. DURANT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-62-3-468 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptUntil recently, only X-ray therapy and the alkylating agents were known to be useful for the treatment of Hodgkin's disease. Over the past 6 years, investigation has shown that the periwinkle derivatives, vinblastine and vincristine, also have considerable use, and of these two, vinblastine is less toxic and more effective in patients with Hodgkin's disease. Much information has been accumulated about this agent, but as yet its place is not fully established. In part, this is due to conflicting reports of its effectiveness and toxicity. Many physicians have been frightened by early reports such as that of Hall (1) in...References1. HALL TC: Chemotherapy of cancer. New Eng. J. Med. 266: 289, 1962. CrossrefMedlineGoogle Scholar2. FROSTGOLDWEINBRYAN JWMIJA: Clinical experience with vincaleukoblastine in far-advanced Hodgkin's disease and various malignant states. Ann. Intern. Med. 58: 584, 1962. Google Scholar3. : Vinblastine in neoplastic disease. Cancer Res. 23: 169, 1963. Google Scholar4. HODESROHNBONDYARDLEYCARPENING MERJWHJMWS: Vincaleukoblastine. IV. A summary of two and one-half years' experience in use of vinblastine. Cancer Chemother. Rep. 16: 401, 1962. MedlineGoogle Scholar5. KARNOFSKY DA: Meaningful clinical classification of therapeutic responses to anti-cancer drugs (editorial). Clin. Pharmacol. Ther. 2: 709, 1961. CrossrefMedlineGoogle Scholar6. BARRYDIAMONDCRAVER RMHDLF: Influence of pregnancy on course of Hodgkin's disease. Amer. J. Obstet. Gynec. 84: 445, 1962. CrossrefMedlineGoogle Scholar7. MILLERDIAMONDCRAVER DGHDLF: Clinical use of chlorambucil. New Eng. J. Med. 261: 525, 1959. CrossrefMedlineGoogle Scholar8. SCOTT JL: The effect of nitrogen mustard and maintenance chlorambucil in the treatment of advanced Hodgkin's disease. Cancer Chemother. Rep. 27: 27, 1963. MedlineGoogle Scholar9. AISENBERG AC: Hodgkin's disease—prognosis, treatment and etiologic and immunologic considerations. New Eng. J. Med. 270: 508, 565, 617, 1964. CrossrefMedlineGoogle Scholar10. LI MC: Management of choriocarcinoma and related tumors of uterus and tests. Med. Clin. N. Amer. 45: 661, 1961. CrossrefMedlineGoogle Scholar11. D'ANGIOFARBERMADDOCK GJSCL: Potentiation of X-ray effects by actinomycin D. Radiology 73: 175, 1959. CrossrefMedlineGoogle Scholar12. WILLIAMS HM: Combination vinblastine-chlorambucil therapy in solid tumors (abstract). Proc. Amer. Ass. Cancer Res. 5: 68, 1964. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York City, New YorkFrom the Lymphoma Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, and the James Ewing Hospital (of the City of New York), and the Department of Medicine, Cornell University Medical College, New York, N. Y.Requests for reprints should be addressed to Mortimer J. Lacher, M.D., Memorial Hospital, 444 East 68th St., New York, N. Y. 10021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPrinciples of Chemotherapy in Hodgkin LymphomaDFT study of the therapeutic potential of phosphorene as a new drug-delivery system to treat cancerRepetitive Existential Plight: The Emotional Impact of Recurrent Serious llinessThe contribution of Gianni Bonadonna to the history of chemotherapyHistorical Overview and Current State of Art in Diagnosis and Treatment of Hodgkin's and Non-Hodgkin's LymphomaHistorical review of lymphomasCommentary on and reprint of DeVita VT Jr, Serpick AA, Carbone PP, Combination chemotherapy in the treatment of advanced Hodgkin's disease, in Annals of Internal Medicine (1970) 73:881–895Escalating drug delivery in cancer chemotherapy: A review of concepts and practice —Part 2The impact of breakthrough clinical trials on survival in population based tumor registriesChemotherapy of Hodgkin's diseaseTreatment of Advanced Hodgkin’s DiseaseTreatment of Hodgkin's diseasePotentially curable neoplasmsRadiochemotherapy for non-Hodgkin's lymphoma in palatine tonsilEvolution in The Treatment Strategy of Hodgkin'S DiseaseChemotherapy of Hodgkin’s and Non-Hodgkin’s LymphomasHodgkin's disease: A curable malignancySynthesis and antitumor activity of 4-[p-[bis(2-chloroethyl)amino]phenyl]butyratesThe eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease. A follow-up reportThe Cure of Disseminated Hodgkin's Disease: Prospects and ProblemsROLF A. STREULI, M.D., JOHN E. ULTMANN, M.D.Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) V.S. CVPP PLUS CCNU (CCVPP) in Hodgkin's diseaseA comparative study of a bcnu containing 4-drug program versus mopp versus 3-drug combinations in advanced Hodgkin's disease.A cooperative study by the cancer and leukemia group BThe chemotherapy of Hodgkin's disease.Past experiences and future directionsRadioimmunoassay of drugs and its clinical applicationHodgkin’s DiseaseA comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (mopp) vs. nitrogen mustard in advanced hodgkin's diseaseCombination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancerDrug Interactions in Cancer ChemotherapyDrugs Five Years Later ProcarbazineSAMUEL D. SPIVACK, M.D.Preparation of 4-[p-[Bis(2-chloroethyl)amino]phenyl]Butyramides as Potential Antitumor Agents IFurther observations on the effect of PHA in conjunction with radiotherapy and chemotherapy on S-180 in Swiss miceChemotherapy of the lymphomasCombination chemotherapy of advanced Hodgkin's disease.A reviewDie LymphogranulomatoseDevelopment of four-drug bcnu combination chemotherapy regimens.(Writing committee for southeastern cancer study group)The Use of Drugs in Combination for the Treatment of CancerA decade of combination chemotherapy of advanced Hodgkin's diseaseMultiple-drug therapy in Hodgkin's diseaseCOMBINATION CHEMOTHERAPY (MOPP) IN THE MANAGEMENT OF ADVANCED HODGKIN'S DISEASE: A PROGRESS REPORT ON 55 PATIENTSCombined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphomaChemotherapy of the LymphomasPresent Position of Radical and Palliative Treatment of Malignant LymphomasCombination chemotherapy in malignant diseaseCombination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseVINCENT T. DEVITA JR., M.D., F.A.C.P., ARTHUR A. SERPICK, M.D., F.A.C.P., PAUL P. CARBONE, M.D.Langzeitbehandlung der fortgeschrittenen vinblastinresistenten Lymphogranulomatose mit Ibenzmethyzin (NatulansR)Comparative effects of vinblastine and procarbazine in advanced Hodgkin's diseaseLong Survival in Hodgkin's DiseaseMORTIMER J. LACHER, M.D., F.A.C.P.Biological Activity of the Terpenoids and Their Derivatives — Recent AdvancesVinblastine in the treatment of advanced Hodgkin's diseaseVinblastine VS. nitrogen mustard therapy of Hodgkin's diseaseHodgkin's Disease Combined Clinical Staff Conference at the National Institutes of HealthSEYMOUR PERRY, M.D., F.A.C.P., LOUIS B. THOMAS, M.D., RALPH E. JOHNSON, M.D., PAUL P. CARBONE, M.D., HARLEY A. HAYNES, M.D.Recent Advances in the Treatment of Malignant HemopathiesHodgkin's DiseaseProgress in the chemotherapy of Hodgkin's diseaseClinical Staging and Treatment of Lymphosarcoma and Reticulum Cell Sarcoma.Classification and Treatment of Hodgkin's Disease 1 March 1965Volume 62, Issue 3Page: 468-476KeywordsCancer treatmentHodgkin lymphomaHospital medicineToxicity Issue Published: 1 March 1965 PDF DownloadLoading ...
No takes yet. Share an insight, caveat, or question.
Mortimer J. Lacher (1965) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: